On May 28, 2025, Lexeo Therapeutics, a clinical-stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, closed its previously announced $80 million private placement equity financing. Wilson Sonsini Goodrich & Rosati advised Lexeo on the transaction.

The private placement was co-led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors, including Adar1 Capital Management, Affinity Healthcare Fund, LP, Ally Bridge Group, Coastlands Capital, Surveyor Capital (a Citadel company), Vestal Point Capital, and Woodline Partners LP. J.P. Morgan and Oppenheimer & Co. acted as co-lead placement agents for the transaction. Baird also acted as placement agent.

Lexeo intends to use the net proceeds from the private placement to advance its ongoing clinical stage programs, as well as for working capital and general corporate purposes.

The Wilson Sonsini team that advised Lexeo on the transaction included Megan Baier, David Sharon, Carole Rosenberg, and Mesha Rivers.

For more information, please see Lexeo’s news release.